Drug/Small Molecule:
diethylcarbamazine

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug/small molecule. To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Carbamazine
  • Carbilazine
  • Diethyl carbamazine
  • Ditrazine base
  • Ethodryl
Trade Names
  • Banocide
  • Bitirazine
  • Caracide
  • Caricide
  • Cypip
  • Decacide
  • Hetrazan
  • Notezine
  • Spatonin
Brand Mixture Names
  • Filaribits Plus 180/136mg Chewable Tablet (Diethylcarbamazine citrate + Oxibendazole)

PharmGKB Accession Id:
PA164748883

Description

An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.

Source: Drug Bank

Indication

Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis. One study showed that diethylcarbamazine's activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. It confirmed the important role of the arachidonic acid metabolic pathway in diethylcarbamazine's mechanism of action in vivo and showes that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1.

Source: Drug Bank

Pharmacology

Diethylcarbamazine is an anthelmintic drug that does not resemble other antiparasitic compounds. It is a synthetic organic compound which is highly specific for several parasites and does not contain any toxic metallic elements. Diethylcarbamazine continues to be the mainstay for treatment of patients with lymphatic filariasis and loiasis.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Partially metabolized to diethylcarbamazine N-oxide.

Source: Drug Bank

Absorption

Readily absorbed following oral administration.

Source: Drug Bank

Half-Life

Approximately 8 hours.

Source: Drug Bank

Toxicity

Oral LD 50 in rat and mouse is 1400 mg/kg and 660 mg/kg, respectively.

Source: Drug Bank

Chemical Properties

Chemical Formula

C10H21N3O

Source: Drug Bank

Isomeric SMILES

CCN(CC)C(=O)N1CCN(CC1)C

Source: Drug Bank

CCN(CC)C(=O)N1CCN(C)CC1

Source: Drug Bank

Canonical SMILES

CCN(CC)C(=O)N1CCN(C)CC1

Source: Drug Bank

Average Molecular Weight

199.2932

Source: Drug Bank

Monoisotopic Molecular Weight

199.168462309

Source: Drug Bank

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00711
KEGG Compound:
C07968
KEGG Drug:
D00803
PubChem Compound:
3052
PubChem Substance:
10169
46506830
Drugs Product Database (DPD):
346667
BindingDB:
50024883
ChemSpider:
2944
Therapeutic Targets Database:
DAP000914

Clinical Trials

These are trials that mention diethylcarbamazine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.